Known targets — ChEMBL curated mechanism
CHRM1DRD2DRD3DRD4HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR2APDE3ASIGMAR1
The experimentally established mechanism targets of Bamipine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 4/20 | 0.54 |
| ▸ | CHRM1 known ✓ | P11229 | 4/20 | 0.54 |
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 0.51 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.43 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.43 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.54 |
| ▸ | DRD1 | P21728 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | CCR5 | P51681 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bamipine SCHEMBL3217102 | 0.90 | OPRM1 (0.59) | KCNH2DRD3CHRM1OPRM1CHRM2 | |
| Bamipine SCHEMBL29626 | 0.88 | KCNH2 (0.66) | KCNH2DRD3CHRM1OPRM1CHRM2 | |
| Bamipine SCHEMBL4424873 | 0.87 | KCNH2 (0.64) | KCNH2DRD3CHRM1OPRM1CHRM2 | |
| Bamipine SCHEMBL443443 | 0.86 | KCNH2 (0.55) | KCNH2DRD3CHRM1OPRM1CHRM2 | |
| Bamipine SCHEMBL1649707 | 0.85 | KCNH2 (0.63) | KCNH2DRD3CHRM1OPRM1CHRM2 | |
| SCHEMBL4492889 | 0.79 | OPRD1 (0.61) | OPRM1OPRD1OPRK1 | |
| SCHEMBL3542065 | 0.77 | KCNH2 (0.56) | KCNH2DRD3CHRM1OPRM1CHRM2 | |
| Thenalidine SCHEMBL4424748 | 0.77 | OPRM1 (0.80) | KCNH2DRD3CHRM1OPRM1CHRM2 | |
| SCHEMBL27703455 | 0.75 | SLC6A2 (0.54) | KCNH2DRD3CHRM1OPRM1CHRM2 | |
| SCHEMBL16307374 | 0.74 | POLB (0.57) | KCNH2DRD3CHRM1OPRM1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0704206-B1 | Pharmaceutical composition | MIKA PHARMA GES FUER DIE ENTWI (DE) | 2002-09-04 | — | — | EP | claimed |
| US-5958379-A | Pharmaceutical composition | MIKA PHARMA GESELLSCHAFT FUER DIE ENTWICKLUNG UND VERMARKTUNG PHARMAZEUTISCHER PRODUCTE MBH (DE) | 1999-09-28 | — | — | US | claimed |
| US-8476318-B2 | Polyethylene glycol esters and cosmetic and/or dermatological preparations | SYMRISE AG (DE) | 2013-07-02 | — | — | US | disclosed |
| EP-2150247-B1 | POLYETHYLENE GLYCOL ESTERS AND COSMETIC AND/OR DERMATOLOGICAL PREPARATIONS | SYMRISE AG (DE) | 2012-10-31 | — | — | EP | disclosed |
| US-20100150854-A1 | POLYETHYLENE GLYCOL ESTERS AND COSMETIC AND/OR DERMATOLOGICAL PREPARATIONS | SYMRISE GMBH & CO., KG (DE) | 2010-06-17 | — | — | US | disclosed |
| EP-2150247-A1 | POLYETHYLENE GLYCOL ESTERS AND COSMETIC AND/OR DERMATOLOGICAL PREPARATIONS | Symrise GmbH & Co. KG (DE) | 2010-02-10 | — | — | EP | disclosed |
| WO-2008128892-A1 | POLYETHYLENE GLYCOL ESTERS AND COSMETIC AND/OR DERMATOLOGICAL PREPARATIONS | SYMRISE GMBH & CO. KG (DE) | 2008-10-30 | — | — | WO | disclosed |
| US-5958379-A | Pharmaceutical composition | MIKA PHARMA GESELLSCHAFT FUER DIE ENTWICKLUNG UND VERMARKTUNG PHARMAZEUTISCHER PRODUCTE MBH (DE) | 1999-09-28 | — | — | US | disclosed |
| US-5919490-A | STIMULATING BLOOD CIRCULATION TO SKIN | LANCASTER GROUP GMBH (DE) | 1999-07-06 | — | — | US | disclosed |
| US-5800835-A | Preparation for improving the blood supply containing hard magnetic particles | LANCASTER GROUP GMBH (DE) | 1998-09-01 | — | — | US | disclosed |
| US-5786384-A | Agents for the treatment and protection of the skin | BEIERSDORF AG (DE) | 1998-07-28 | — | — | US | disclosed |
| US-5686102-A | ASYMMETRIC, LAMELLAR AGGREGATES CONTAINING PHOSPHOLIPIDS, DRUG, AND FLUOROCARBON | LANCASTER GROUP AG (DE) | 1997-11-11 | — | — | US | disclosed |
| US-5652261-A | ADMINISTERING VITAMIN E MIXTURE; SUNSCREEN, ANTIINFLAMMATORY, ANTIAGING, AND WOUND HEALING AGENTS | BEIERSDORF AG (DE) | 1997-07-29 | — | — | US | disclosed |
| US-5541220-A | SKIN DISORDERS, WOUND HEALING AGENTS, ANTIINFLAMMATORY AGENTS AND RADIATION RESISTANCE | BEIERSDORF AG (DE) | 1996-07-30 | — | — | US | disclosed |
| US-4938960-A | VITAMIN E, SYNERGISTIC | BEIERSDORF AG (DE) | 1990-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100150854-A1 | POLYETHYLENE GLYCOL ESTERS AND COSMETIC AND/OR DERMATOLOGICAL PREPARATIONS | CUTA, LIPA, NAPEPLD | DRD3 2267/4885CHRM1 4869/4885DRD2 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.